An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer
Authors
Keywords
-
Journal
Scientific Reports
Volume 9, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-09-16
DOI
10.1038/s41598-019-49809-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2017) Sung-Bae Kim et al. LANCET ONCOLOGY
- Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer
- (2016) Gary Beale et al. BRITISH JOURNAL OF CANCER
- A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors
- (2016) Philip Eliades et al. CANCER BIOLOGY & THERAPY
- Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors
- (2016) Patricia Mucci LoRusso JOURNAL OF CLINICAL ONCOLOGY
- COSMIC: somatic cancer genetics at high-resolution
- (2016) Simon A. Forbes et al. NUCLEIC ACIDS RESEARCH
- EGFR and MEK Blockade in Triple Negative Breast Cancer Cells
- (2015) Monica Rosaria Maiello et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma
- (2015) Christian Posch et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models
- (2015) C. Hu et al. MOLECULAR CANCER THERAPEUTICS
- TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data
- (2015) Antonio Colaprico et al. NUCLEIC ACIDS RESEARCH
- Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer
- (2015) Jangsoon Lee et al. Journal of Cancer
- CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors
- (2014) Sadhna R. Vora et al. CANCER CELL
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
- The clinical development of MEK inhibitors
- (2014) Yujie Zhao et al. Nature Reviews Clinical Oncology
- Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer
- (2013) Kamal S. Saini et al. CANCER TREATMENT REVIEWS
- Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
- (2013) J. Lin et al. CLINICAL CANCER RESEARCH
- A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours
- (2013) Jeffrey R. Infante et al. EUROPEAN JOURNAL OF CANCER
- Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
- (2012) James S. Duncan et al. CELL
- Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer
- (2012) T. Sangai et al. CLINICAL CANCER RESEARCH
- The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
- (2012) T. Shimizu et al. CLINICAL CANCER RESEARCH
- Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
- (2012) D. W. Craig et al. MOLECULAR CANCER THERAPEUTICS
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- cAMP signalling protects proximal tubular epithelial cells from cisplatin-induced apoptosis via activation of Epac
- (2011) Yu Qin et al. BRITISH JOURNAL OF PHARMACOLOGY
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
- (2010) H. Hirai et al. MOLECULAR CANCER THERAPEUTICS
- Enrichment Map: A Network-Based Method for Gene-Set Enrichment Visualization and Interpretation
- (2010) Daniele Merico et al. PLoS One
- Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition
- (2009) O. K. Mirzoeva et al. CANCER RESEARCH
- In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
- (2009) K. P. Hoeflich et al. CLINICAL CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started